JP2020510049A - 自閉症スペクトラム障害の処置のための方法 - Google Patents

自閉症スペクトラム障害の処置のための方法 Download PDF

Info

Publication number
JP2020510049A
JP2020510049A JP2019549537A JP2019549537A JP2020510049A JP 2020510049 A JP2020510049 A JP 2020510049A JP 2019549537 A JP2019549537 A JP 2019549537A JP 2019549537 A JP2019549537 A JP 2019549537A JP 2020510049 A JP2020510049 A JP 2020510049A
Authority
JP
Japan
Prior art keywords
cord blood
months
behavioral
patient
autism spectrum
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2019549537A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020510049A5 (https=
Inventor
ジョアン カーツバーグ，
ジョアン カーツバーグ，
ジェラルディン ドーソン，
ジェラルディン ドーソン，
ジェシー トロイ，
ジェシー トロイ，
ジェシカ サン，
ジェシカ サン，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Duke University
Original Assignee
Duke University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Duke University filed Critical Duke University
Publication of JP2020510049A publication Critical patent/JP2020510049A/ja
Publication of JP2020510049A5 publication Critical patent/JP2020510049A5/ja
Pending legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/05—Detecting, measuring or recording for diagnosis by means of electric currents or magnetic fields; Measuring using microwaves or radio waves
    • A61B5/055—Detecting, measuring or recording for diagnosis by means of electric currents or magnetic fields; Measuring using microwaves or radio waves involving electronic [EMR] or nuclear [NMR] magnetic resonance, e.g. magnetic resonance imaging
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/16—Devices for psychotechnics; Testing reaction times ; Devices for evaluating the psychological state
    • A61B5/163—Devices for psychotechnics; Testing reaction times ; Devices for evaluating the psychological state by tracking eye movement, gaze, or pupil change
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/48—Other medical applications
    • A61B5/4848—Monitoring or testing the effects of treatment, e.g. of medication
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/48—Reproductive organs
    • A61K35/51—Umbilical cord; Umbilical cord blood; Umbilical stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pathology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Cell Biology (AREA)
  • Medical Informatics (AREA)
  • Surgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Psychiatry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Reproductive Health (AREA)
  • Zoology (AREA)
  • Virology (AREA)
  • Radiology & Medical Imaging (AREA)
  • High Energy & Nuclear Physics (AREA)
  • Psychology (AREA)
  • Dermatology (AREA)
  • Developmental Disabilities (AREA)
  • Hospice & Palliative Care (AREA)
JP2019549537A 2017-03-13 2018-03-13 自閉症スペクトラム障害の処置のための方法 Pending JP2020510049A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762470431P 2017-03-13 2017-03-13
US62/470,431 2017-03-13
PCT/US2018/022174 WO2018169952A1 (en) 2017-03-13 2018-03-13 Methods for the treatment of autism spectrum disorders

Publications (2)

Publication Number Publication Date
JP2020510049A true JP2020510049A (ja) 2020-04-02
JP2020510049A5 JP2020510049A5 (https=) 2021-04-22

Family

ID=63522569

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019549537A Pending JP2020510049A (ja) 2017-03-13 2018-03-13 自閉症スペクトラム障害の処置のための方法

Country Status (4)

Country Link
US (2) US10912801B2 (https=)
JP (1) JP2020510049A (https=)
KR (1) KR20190124300A (https=)
WO (1) WO2018169952A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112113921A (zh) * 2020-08-12 2020-12-22 华南农业大学 一种用于待测样品间麦角硫因含量高低的高通量检测方法及其应用

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025064634A1 (en) * 2023-09-20 2025-03-27 Rutgers, The State University Of New Jersey Techniques for measuring or modifying control in digital interactions

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004500824A (ja) * 2000-03-09 2004-01-15 クリオ−セル　インターナショナル　インコーポレーティッド 脳および脊髄の修復のための神経組織源としてのヒト臍帯血
WO2014018774A1 (en) * 2012-07-26 2014-01-30 The Regents Of The University Of California Screening, diagnosis and prognosis of autism and other developmental disorders
KR20140066550A (ko) * 2012-11-23 2014-06-02 의료법인 성광의료재단 제대혈 유래 줄기세포와 에리트로포이에틴을 포함하는 유전자 질환을 포함하는 발달장애 치료용 약학적 조성물

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1664336A2 (en) 2003-09-11 2006-06-07 University College Cork-National University of Ireland, Cork A detection method for autism and related disorders

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004500824A (ja) * 2000-03-09 2004-01-15 クリオ−セル　インターナショナル　インコーポレーティッド 脳および脊髄の修復のための神経組織源としてのヒト臍帯血
WO2014018774A1 (en) * 2012-07-26 2014-01-30 The Regents Of The University Of California Screening, diagnosis and prognosis of autism and other developmental disorders
KR20140066550A (ko) * 2012-11-23 2014-06-02 의료법인 성광의료재단 제대혈 유래 줄기세포와 에리트로포이에틴을 포함하는 유전자 질환을 포함하는 발달장애 치료용 약학적 조성물

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
CYTOTHERAPY, 2016, VOL.18, ISSUE 6, SUPPL., P.S112, ABSTRACT NO.193, JPN6022004870, ISSN: 0004928630 *
JOURNAL OF CLINICAL REHABILITATIVE TISSUE ENGINEERING RESEARCH, 2011, VOL.15, NO.23, PP.4359-4362, JPN6022004872, ISSN: 0004699214 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112113921A (zh) * 2020-08-12 2020-12-22 华南农业大学 一种用于待测样品间麦角硫因含量高低的高通量检测方法及其应用
CN112113921B (zh) * 2020-08-12 2021-11-26 华南农业大学 一种用于待测样品间麦角硫因含量高低的高通量检测方法及其应用

Also Published As

Publication number Publication date
KR20190124300A (ko) 2019-11-04
US10912801B2 (en) 2021-02-09
US20210244772A1 (en) 2021-08-12
WO2018169952A1 (en) 2018-09-20
US11813294B2 (en) 2023-11-14
US20200069741A1 (en) 2020-03-05

Similar Documents

Publication Publication Date Title
Dawson et al. A phase II randomized clinical trial of the safety and efficacy of intravenous umbilical cord blood infusion for treatment of children with autism spectrum disorder
Sharma et al. Autologous bone marrow mononuclear cell therapy for autism: an open label proof of concept study
Munesue et al. Oxytocin for male subjects with autism spectrum disorder and comorbid intellectual disabilities: a randomized pilot study
Wright et al. Pet dogs improve family functioning and reduce anxiety in children with autism spectrum disorder
Mukaetova‐Ladinska et al. Ageing in people with autistic spectrum disorder
Frank-Briggs et al. Knowledge and attitudes of parents toward children with epilepsy
Colebunders et al. Ivermectin treatment in patients with onchocerciasis-associated epilepsy: protocol of a randomized clinical trial
US11813294B2 (en) Methods for the treatment of autism spectrum disorders
Ecury‐Goossen et al. Neurodevelopmental outcome after neonatal perforator stroke
US12491210B2 (en) Methods of assessing and treating autism spectrum disorders using human umbilical cord tissue-derived mesenchymal stromal cells
Ahmed et al. An approach to the evaluation of a patient for seizures and epilepsy
Fuh et al. Measuring Alzheimer's disease progression with transition probabilities in the Taiwanese population
Vannucchi Depressive and bipolar disorders in persons with intellectual disability and low-functioning autism spectrum disorder. The development and first validation of a new diagnostic tool (SPADD-M)
Zaro et al. Description of Clinician-Diagnosed Regression at Time of Autism Spectrum Disorder Diagnosis in Toddlers
Robertson et al. The neuropsychiatry and neuropsychology of Gilles de la Tourette syndrome
Bouteloup et al. The Value of the Rorschach Method in Clinical Assessment of Migraine Patients
Macenski et al. Evaluation and Treatment of New-Onset Psychotic Symptoms in a Patient with Autism Spectrum Disorder and Multiple Autoimmune Disorders
HK40045701A (en) Methods of treating autism spectrum disorders using human umbilical cord tissue-derived mesenchymal stromal cells
Moulin A qualitative study of adolescents with medically unexplained symptoms and their parents
Partridge Caregiver's perception of epilepsy treatment, quality of life and comorbidities in an international cohort of CDKL5 patients
May et al. Using Functional Behavioral Assessment to Study the Effects of Citalopram on the Obsessive-Compulsive Verbalizations of a Woman
Richards An animal model of autism: remediation with tactile stimulation
Assane Human Taenia Solium Cysticercosis in the district of Angónia, Mozambique: prevalence rates and clinical aspects
Ali You Have New Patients! Patient
US20200016213A1 (en) Methods of Treating Cerebral Palsy Using High Dose Allogeneic Umbilical Cord Blood

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210305

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20210305

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220204

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20220502

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20220622

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220804

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20221125